Evidence continues to accumulate that a deficiency of estrogen action on bone is a major contributor to bone loss in elderly men. Because of feminizing effects, estrogen cannot be given as treatment. However, raloxifene is a non-feminizing form of estrogen that has an estrogen agonist effect on bone. The purpose of this study is to compare the tolerance and long-term effects of raloxifene versus ploacebo on bone resorption and bone formation in elderly men as assessed by measurement of biochemical markers.
Showing the most recent 10 out of 1267 publications